ICOSAPENT ETHYL REDUCES POTENTIALLY ATHEROGENIC LIPID AND INFLAMMATORY MARKERS IN HIGH-RISK STATIN-TREATED PATIENTS WITH PERSISTENT HIGH TRIGLYCERIDES, EGFR < 90 ML/MIN/1.73 M2, AND ELEVATED HIGH-SENSITIVITY C-REACTIVE PROTEIN >= 2.0 MG/L